Clinical trial
BI 2536 Second Line Monotherapy in SCLC
NCT00412880 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00412880 |
|---|---|
| Title | BI 2536 Second Line Monotherapy in SCLC |
| Official title | An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell |
| Intervention type | Drug |
| Interventions | BI 2536 |
| Enrollment | 23 |
| Start date | Feb 14, 2007 |
| Primary completion | Jun 30, 2008 |
| Completion | Jun 30, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Jun 22, 2022 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: